Literature DB >> 21968213

Severe neonatal hyperbilirubinemia and kernicterus: are these still problems in the third millennium?

Michael Kaplan1, Ruben Bromiker, Cathy Hammerman.   

Abstract

Despite efforts to eliminate permanent and irreversible brain damage due to bilirubin encephalopathy and kernicterus, these conditions continue to accompany us into the third millennium. This phenomenon occurs not only in developing countries with emerging medical systems, but in Westernized countries as well. Comprehensive guidelines to detect newborns with jaundice and treat those in whom hyperbilirubinemia has already developed have been formulated in several countries, but have not been successful in completely eliminating the problem. In this appraisal of the situation we review selected aspects of bilirubin encephalopathy and/or kernicterus. We highlight recent reports of severe hyperbilirubinemia and kernicterus, discuss some of the factors responsible for the continuing appearance of these conditions, and briefly review what can be done to decrease bilirubin-related morbidity and mortality to the minimum.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21968213     DOI: 10.1159/000330055

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  35 in total

1.  Prebiotics for the prevention of hyperbilirubinaemia in neonates.

Authors:  Amir Mohammad Armanian; Shayesteh Jahanfar; Awat Feizi; Nima Salehimehr; Mitra Molaeinezhad; Erfan Sadeghi
Journal:  Cochrane Database Syst Rev       Date:  2019-08-13

Review 2.  Prevention of Kernicterus in South Asia: role of neonatal G6PD deficiency and its identification.

Authors:  Yassar H Arain; Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2014-04-26       Impact factor: 1.967

3.  Reliability of transcutaneous bilirubin determination based on skin color determined by a neonatal skin color scale of our own.

Authors:  Silvia Maya-Enero; Júlia Candel-Pau; Jordi Garcia-Garcia; Xavier Duran-Jordà; María Ángeles López-Vílchez
Journal:  Eur J Pediatr       Date:  2021-01-06       Impact factor: 3.183

4.  Predictive value of cord blood bilirubin for hyperbilirubinemia in neonates at risk for maternal-fetal blood group incompatibility and hemolytic disease of the newborn.

Authors:  K Calkins; D Roy; L Molchan; L Bradley; T Grogan; D Elashoff; V Walker
Journal:  J Neonatal Perinatal Med       Date:  2015

Review 5.  Bilirubin nomograms for identification of neonatal hyperbilirubinemia in healthy term and late-preterm infants: a systematic review and meta-analysis.

Authors:  Zhang-Bin Yu; Shu-Ping Han; Chao Chen
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

6.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 7.  Glucose-6-Phosphate Dehydrogenase Deficiency and the Need for a Novel Treatment to Prevent Kernicterus.

Authors:  Anna D Cunningham; Sunhee Hwang; Daria Mochly-Rosen
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

8.  Lipid peroxidation, DNA damage and total antioxidant status in neonatal hyperbilirubinemia.

Authors:  S Basu; D De; H Dev Khanna; A Kumar
Journal:  J Perinatol       Date:  2014-03-27       Impact factor: 2.521

9.  Intestinal NCoR1, a regulator of epithelial cell maturation, controls neonatal hyperbilirubinemia.

Authors:  Shujuan Chen; Wenqi Lu; Mei-Fei Yueh; Eva Rettenmeier; Miao Liu; Miles Paszek; Johan Auwerx; Ruth T Yu; Ronald M Evans; Kepeng Wang; Michael Karin; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

10.  Effects of bilirubin on neutrophil responses in newborn infants.

Authors:  Barry Weinberger; Faith E Archer; Suganya Kathiravan; Daniel S Hirsch; Alan M Kleinfeld; Anna M Vetrano; Thomas Hegyi
Journal:  Neonatology       Date:  2012-11-22       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.